Investigating determinants of macular pigment optical density and macular pigment distribution in adults aged 45--73: Can enhanced analytical techniques improve the ability to predict macular pigment status?

This research assessed the relationships of dietary, sex, and biochemical factors to macular pigment optical density (MPOD) and macular pigment (MP) distribution in 108 adults. Dietary assessment tools were evaluated for their ability to predict MP status. Macular pigment was assessed at four foveal sites and one parafoveal site. An average composite macular pigment value (CMPV) was calculated based on the MPOD results. Group mean MPOD results from most to least central retinal locations, were 0.43 (SE +/- 0.017), 0.36 (SE +/- 0.013), 0.28 (SE +/- 0.012), and 0.13 (SE +/- 0.008), respectively. The CMTV was 0.26 (SE +/- 0.0 11). Those with blue iris color were found to have higher MPOD at the 1.00° (p = 0.008), and 2.00° (p = 0.01) sites and CWV results (p = 0.02) compared to those with hazel eyes. Significantly lower MPOD were evident at the 1.00° (p = 0.02) and 2.00° (p = 0.001) sites and for CMTV (p = 0.02) when BMI ≥ 27 compared to BMI \u3c 27. Higher MPOD were associated with higher intakes of fruits and vegetables using average consumption estimations derived from a seven item fruit and vegetable screening tool, while a 24-hour carotenoid guided food recall did not predict MPOD. Multiple significant linear relationships were detected for dietary intakes of the carotenoids lutein and beta-cryptoxanthin based on FFQ results Additional nutrients with multiple significant associations were vitamins A and C, and iron. Mean serum lutein and lutein/zeaxanthin concentrations for the sample were significantly associated with MPOD at the 0.167°, 0.50°, 1.00° sites, and CMPV results. Cholesterol, LDL-C, and HDL-C were not associated with MPOD while triglycerides were significantly associated with MPOD at the 0.167° (p = 0.03) and 1.00° (p = 0.02) sites. Fasting serum lipoproteins of total cholesterol and triglycerides concentrations were significantly associated with some serum carotenoid concentrations, while LDL-C and HDL-C were not significantly associated with serum carotenoid concentrations

Community Capacity Building in the Designation of the Tortugas Ecological Reserve

The remote Tortugas region of the Florida Keys, located over 225 km from the continental United States, is an area of high coral diversity, excellent water quality, and productive fisheries. Located at the juncture of major ocean currents, the Tortugas potentially serves as a source and sink for marine larvae. The Florida Keys National Marine Sanctuary initiated a process in 1998 to create a fully protected ecological reserve in the Tortugas to conserve these resources. Reserve design emphasized community input and consensus-based decision-making. Critical to success was a diverse working group of stakeholders and government agencies. In July 2001, after receiving extensive public comment and the necessary agency approvals for designation, the Sanctuary implemented a 518-km2 Tortugas Ecological Reserve. This fully protected marine reserve is expected to preserve biodiversity, maintain ecosystem integrity, and act as a reference site to discriminate between natural and anthropogenic changes to the ecosystem. The Tortugas Ecological Reserve complements the Sanctuary’s existing network of 23 fully protected zones, instituted in 1997 to protect marine resources from overuse, conserve biodiversity, and separate uses. The Tortugas Ecological Reserve is the largest fully protected marine reserve in the United States

Speaking vocabulary of first grade children

Thesis (Ed.M.)--Boston Universit

Status of Coral Reefs in the US Caribbean and Gulf of Mexico: Florida, Texas, Puerto Rico, US Virgin Islands and Navassa

The following report on the status of US Caribbean coral reef ecosystems has been summarised from more extensive reports submitted to the US Coral Reef Task Force (USCRTF) working group that implemented in 2000 ‘A National Program to Assess, Inventory, and Monitor US Coral Reef Ecosystems’. The more-lengthy reports are also the basis for the biennial-issued document, ‘Status and Trends of US Coral Reef Ecosystems’. Each author is a recognised technical expert with responsibility for monitoring and/or managing aspects of their respective coral reef ecosystems

Symmetric dimethylarginine (SDMA) is a stronger predictor of mortality risk than asymmetric dimethylarginine (ADMA) amongst older people with kidney disease

Background Circulating asymmetric (ADMA) and symmetric dimethylarginine (SDMA) are increased in patients with kidney disease. SDMA is considered a good marker of glomerular filtration rate (GFR) whilst ADMA is a marker of cardiovascular risk. However, a link between SDMA and all-cause mortality has been reported. In the present study we evaluated both dimethylarginines as risk and GFR markers in a cohort of elderly white individuals, both with and without CKD. Methods GFR was measured in 394 individuals aged >74 years using an iohexol clearance method. Plasma ADMA, SDMA and iohexol were measured simultaneously using isotope dilution tandem mass spectrometry. Results Plasma ADMA concentrations were increased (P60 mL/min/1.73 m², but did not differ (P>0.05) between those with GFR 30-59 mL/min/1.73 m² and <30 mL/min/1.73 m². Plasma SDMA increased consistently across declining GFR categories (P<0.0001). GFR had an independent effect on plasma ADMA concentration whilst GFR, gender, body mass index and haemoglobin had independent effects on plasma SDMA concentration. Participants were followed for a median of 33 months. There were 65 deaths. High plasma ADMA (P=0.0412) and SDMA (P<0.0001) concentrations were independently associated with reduced survival. Conclusions Amongst elderly white individuals with a range of kidney function, SDMA was a better marker of GFR and a stronger predictor of outcome than ADMA. Future studies should further evaluate the role of SDMA as a marker of outcome and assess its potential value as a marker of GFR

The State of Coral Reef Ecosystems of the United States and Pacific Freely Associated States: 2002

Called for by the U.S. Coral Reef Task Force’s (USCRTF) National Action Plan to Conserve Coral Reefs, this is the first biennial report on the condition of coral reefs. It is the scientific baseline for subsequent reports on the health of U.S. coral reef ecosystems that are to be used by NOAA and others to evaluate the efficacy of coral reef conservation and management practices. The National Oceanic and Atmospheric Administration’s National Ocean Service led the development of this report. It was authored by 38 experts and supported by 79 contributors from government agencies and non-governmental organizations across the nation and internationally. Over 100 Task Force members and other notable scientists have reviewed this document

Ten-year mortality, disease progression, and treatment-related side effects in men with localised prostate cancer from the ProtecT randomised controlled trial according to treatment received

Background The ProtecT trial reported intention-to-treat analysis of men with localised prostate cancer randomly allocated to active monitoring (AM), radical prostatectomy, and external beam radiotherapy. Objective To report outcomes according to treatment received in men in randomised and treatment choice cohorts. Design, setting, and participants This study focuses on secondary care. Men with clinically localised prostate cancer at one of nine UK centres were invited to participate in the treatment trial comparing AM, radical prostatectomy, and radiotherapy. Intervention Two cohorts included 1643 men who agreed to be randomised and 997 who declined randomisation and chose treatment. Outcome measurements and statistical analysis Analysis was carried out to assess mortality, metastasis and progression and health-related quality of life impacts on urinary, bowel, and sexual function using patient-reported outcome measures. Analysis was based on comparisons between groups defined by treatment received for both randomised and treatment choice cohorts in turn, with pooled estimates of intervention effect obtained using meta-analysis. Differences were estimated with adjustment for known prognostic factors using propensity scores. Results and limitations According to treatment received, more men receiving AM died of PCa (AM 1.85%, surgery 0.67%, radiotherapy 0.73%), whilst this difference remained consistent with chance in the randomised cohort (p = 0.08); stronger evidence was found in the exploratory analyses (randomised plus choice cohort) when AM was compared with the combined radical treatment group (p = 0.003). There was also strong evidence that metastasis (AM 5.6%, surgery 2.4%, radiotherapy 2.7%) and disease progression (AM 20.35%, surgery 5.87%, radiotherapy 6.62%) were more common in the AM group. Compared with AM, there were higher risks of sexual dysfunction (95% at 6 mo) and urinary incontinence (55% at 6 mo) after surgery, and of sexual dysfunction (88% at 6 mo) and bowel dysfunction (5% at 6 mo) after radiotherapy. The key limitations are the potential for bias when comparing groups defined by treatment received and changes in the protocol for AM during the lengthy follow-up required in trials of screen-detected PCa. Conclusions Analyses according to treatment received showed increased rates of disease-related events and lower rates of patient-reported harms in men managed by AM compared with men managed by radical treatment, and stronger evidence of greater PCa mortality in the AM group. Patient summary More than 95 out of every 100 men with low or intermediate risk localised prostate cancer do not die of prostate cancer within 10 yr, irrespective of whether treatment is by means of monitoring, surgery, or radiotherapy. Side effects on sexual and bladder function are better after active monitoring, but the risks of spreading of prostate cancer are more common

Functional and quality of life outcomes of localised prostate cancer treatments (prostate testing for cancer and treatment [ProtecT] study)

Objective To investigate the functional and quality of life (QoL) outcomes of treatments for localised prostate cancer and inform treatment decision-making. Patients and Methods Men aged 50–69 years diagnosed with localised prostate cancer by prostate-specific antigen testing and biopsies at nine UK centres in the Prostate Testing for Cancer and Treatment (ProtecT) trial were randomised to, or chose one of, three treatments. Of 2565 participants, 1135 men received active monitoring (AM), 750 a radical prostatectomy (RP), 603 external-beam radiotherapy (EBRT) with concurrent androgen-deprivation therapy (ADT) and 77 low-dose-rate brachytherapy (BT, not a randomised treatment). Patient-reported outcome measures (PROMs) completed annually for 6 years were analysed by initial treatment and censored for subsequent treatments. Mixed effects models were adjusted for baseline characteristics using propensity scores. Results Treatment-received analyses revealed different impacts of treatments over 6 years. Men remaining on AM experienced gradual declines in sexual and urinary function with age (e.g., increases in erectile dysfunction from 35% of men at baseline to 53% at 6 years and nocturia similarly from 20% to 38%). Radical treatment impacts were immediate and continued over 6 years. After RP, 95% of men reported erectile dysfunction persisting for 85% at 6 years, and after EBRT this was reported by 69% and 74%, respectively (P < 0.001 compared with AM). After RP, 36% of men reported urinary leakage requiring at least 1 pad/day, persisting for 20% at 6 years, compared with no change in men receiving EBRT or AM (P < 0.001). Worse bowel function and bother (e.g., bloody stools 6% at 6 years and faecal incontinence 10%) was experienced by men after EBRT than after RP or AM (P < 0.001) with lesser effects after BT. No treatment affected mental or physical QoL. Conclusion Treatment decision-making for localised prostate cancer can be informed by these 6-year functional and QoL outcomes